Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 378 |
Udgave nummer | 9809 |
Sider (fra-til) | 2081-7 |
Antal sider | 7 |
ISSN | 0140-6736 |
DOI | |
Status | Udgivet - 2011 |
ID: 36070262